179 related articles for article (PubMed ID: 32291397)
1. Transcriptomic data helps refining classification of pulmonary carcinoid tumors with increased mitotic counts.
Sazonova O; Manem V; Orain M; Khoshkrood-Mansoori B; Gaudreault N; Desmeules P; Bossé Y; Joubert P
Mod Pathol; 2020 Sep; 33(9):1712-1721. PubMed ID: 32291397
[TBL] [Abstract][Full Text] [Related]
2. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA; Junker K
Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
[TBL] [Abstract][Full Text] [Related]
3. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N; Desmeules P; Litvak AM; Pietanza MC; Santos-Zabala ML; Ni A; Montecalvo J; Chang JC; Beras A; Preeshagul IR; Sabari JK; Rudin CM; Ladanyi M; Klimstra DS; Travis WD; Lai WC
Mod Pathol; 2019 Jul; 32(8):1106-1122. PubMed ID: 30923345
[TBL] [Abstract][Full Text] [Related]
4. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
[TBL] [Abstract][Full Text] [Related]
6. Clinic and genetic similarity assessments of atypical carcinoid, neuroendocrine neoplasm with atypical carcinoid morphology and elevated mitotic count and large cell neuroendocrine carcinoma.
Zhang Y; Wang W; Hu Q; Liang Z; Zhou P; Tang Y; Jiang L
BMC Cancer; 2022 Mar; 22(1):321. PubMed ID: 35331190
[TBL] [Abstract][Full Text] [Related]
7. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
8. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.
Travis WD; Linnoila RI; Tsokos MG; Hitchcock CL; Cutler GB; Nieman L; Chrousos G; Pass H; Doppman J
Am J Surg Pathol; 1991 Jun; 15(6):529-53. PubMed ID: 1709558
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E
J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341
[TBL] [Abstract][Full Text] [Related]
11. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
[TBL] [Abstract][Full Text] [Related]
12. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.
Alcala N; Leblay N; Gabriel AAG; Mangiante L; Hervas D; Giffon T; Sertier AS; Ferrari A; Derks J; Ghantous A; Delhomme TM; Chabrier A; Cuenin C; Abedi-Ardekani B; Boland A; Olaso R; Meyer V; Altmuller J; Le Calvez-Kelm F; Durand G; Voegele C; Boyault S; Moonen L; Lemaitre N; Lorimier P; Toffart AC; Soltermann A; Clement JH; Saenger J; Field JK; Brevet M; Blanc-Fournier C; Galateau-Salle F; Le Stang N; Russell PA; Wright G; Sozzi G; Pastorino U; Lacomme S; Vignaud JM; Hofman V; Hofman P; Brustugun OT; Lund-Iversen M; Thomas de Montpreville V; Muscarella LA; Graziano P; Popper H; Stojsic J; Deleuze JF; Herceg Z; Viari A; Nuernberg P; Pelosi G; Dingemans AMC; Milione M; Roz L; Brcic L; Volante M; Papotti MG; Caux C; Sandoval J; Hernandez-Vargas H; Brambilla E; Speel EJM; Girard N; Lantuejoul S; McKay JD; Foll M; Fernandez-Cuesta L
Nat Commun; 2019 Aug; 10(1):3407. PubMed ID: 31431620
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary Carcinoids and Low-Grade Gastrointestinal Neuroendocrine Tumors Show Common MicroRNA Expression Profiles, Different from Adenocarcinomas and Small Cell Carcinomas.
Yoshimoto T; Motoi N; Yamamoto N; Nagano H; Ushijima M; Matsuura M; Okumura S; Yamaguchi T; Fukayama M; Ishikawa Y
Neuroendocrinology; 2018; 106(1):47-57. PubMed ID: 28208131
[TBL] [Abstract][Full Text] [Related]
14. Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency.
Laflamme P; Mansoori BK; Sazanova O; Orain M; Couture C; Simard S; Trahan S; Manem V; Joubert P
Hum Pathol; 2020 Dec; 106():74-81. PubMed ID: 33007357
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
16. The Role of Histologic Grading and Ki-67 Index in Predicting Outcomes in Pulmonary Carcinoid Tumors.
Dermawan JKT; Farver CF
Am J Surg Pathol; 2020 Feb; 44(2):224-231. PubMed ID: 31490236
[TBL] [Abstract][Full Text] [Related]
17. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid.
Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M
J BUON; 2019; 24(1):256-266. PubMed ID: 30941978
[TBL] [Abstract][Full Text] [Related]
18. Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Pelosi G; Bianchi F; Dama E; Simbolo M; Mafficini A; Sonzogni A; Pilotto S; Harari S; Papotti M; Volante M; Fontanini G; Mastracci L; Albini A; Bria E; Calabrese F; Scarpa A
Virchows Arch; 2018 Apr; 472(4):567-577. PubMed ID: 29388013
[TBL] [Abstract][Full Text] [Related]
19. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
20. Classification of pulmonary neuroendocrine tumors: new insights.
Pelosi G; Sonzogni A; Harari S; Albini A; Bresaola E; Marchiò C; Massa F; Righi L; Gatti G; Papanikolaou N; Vijayvergia N; Calabrese F; Papotti M
Transl Lung Cancer Res; 2017 Oct; 6(5):513-529. PubMed ID: 29114468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
